Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)

Yazar
Ardavanis, A.
Basaran, M.
Malik, Z. I.
Di Lorenzo, G.
Heidenreich, A.
Hitier, S.
Van Oort, I.
Saad, F.
De Schultz, W.
Parente, P.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/52463
Koleksiyonlar